Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H26ClNO5.ClH |
Molecular Weight | 432.338 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC(=O)COC1=C(Cl)C2=C(C=C1)C(C)=C(CCN(CC)CC)C(=O)O2
InChI
InChIKey=CCCZJRFQJNGCCU-UHFFFAOYSA-N
InChI=1S/C20H26ClNO5.ClH/c1-5-22(6-2)11-10-15-13(4)14-8-9-16(26-12-17(23)25-7-3)18(21)19(14)27-20(15)24;/h8-9H,5-7,10-12H2,1-4H3;1H
Molecular Formula | C20H26ClNO5 |
Molecular Weight | 395.877 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Cloricromen a drug that inhibits platelet aggregation in man and in experimental thrombosis. Experiments on rodents have revealed that cloricromene which reduced tumor necrosis factor production, could be useful in the treatment of periodontitis. In addition, it could be potentially useful in ischemic-retinal diseases where amelioration of blood flow and inflammation is desirable. However, experiments with patients with cerebrovascular occlusive disease didn’t shown any effect of cloricromen on coagulative variables.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map04064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15322736 |
PubMed
Title | Date | PubMed |
---|---|---|
Cloricromene, a semi-synthetic coumarin derivative, inhibits tumor necrosis factor-alpha production at a pre-transcriptional level. | 2001 Apr 27 |
|
Cloricromene in endotoxemia: role of NF-kappaB. | 2004 Aug |
|
Cloricromene, a coumarine derivative, reduced the development of periodontitis in rats. | 2006 Apr |
|
Protective effects of a coumarin derivative in diabetic rats. | 2009 Aug |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7867874
Twenty patients with a history of atherothrombotic stroke received cloricromen (100 mg, twice daily) for 30 days in order to evaluate its effects on plasma fibrinogen, antithrombin III, and other variables of the haemostatic system
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:53:19 GMT 2023
by
admin
on
Fri Dec 15 16:53:19 GMT 2023
|
Record UNII |
931696CA9T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
74697-28-2
Created by
admin on Fri Dec 15 16:53:19 GMT 2023 , Edited by admin on Fri Dec 15 16:53:19 GMT 2023
|
PRIMARY | |||
|
m3663
Created by
admin on Fri Dec 15 16:53:19 GMT 2023 , Edited by admin on Fri Dec 15 16:53:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
16219127
Created by
admin on Fri Dec 15 16:53:19 GMT 2023 , Edited by admin on Fri Dec 15 16:53:19 GMT 2023
|
PRIMARY | |||
|
DTXSID9046499
Created by
admin on Fri Dec 15 16:53:19 GMT 2023 , Edited by admin on Fri Dec 15 16:53:19 GMT 2023
|
PRIMARY | |||
|
100000087958
Created by
admin on Fri Dec 15 16:53:19 GMT 2023 , Edited by admin on Fri Dec 15 16:53:19 GMT 2023
|
PRIMARY | |||
|
SUB01371MIG
Created by
admin on Fri Dec 15 16:53:19 GMT 2023 , Edited by admin on Fri Dec 15 16:53:19 GMT 2023
|
PRIMARY | |||
|
931696CA9T
Created by
admin on Fri Dec 15 16:53:19 GMT 2023 , Edited by admin on Fri Dec 15 16:53:19 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |